Hester Biosciences' Nepal JV launches Live Thermo-tolerant PPR Vaccine

23 Nov 2020 Evaluate

Hester Biosciences' joint venture (JV) company -- Hester Biosciences Nepal has successfully developed and launched its Live Thermo-tolerant PPR (Peste Des Petits) Vaccine - Nigerian 75/1 Strain, under the brand name Live Thermovac PPR Vaccine.

Hester Nepal recently got the regulatory approval and marketing authorisation from Department of Drug Administration (DDA), Nepal, for its commercial production and marketing. The vaccine has also been tested for thermo-stability and has received a quality certification from The Pan African Veterinary Centre of the African Union (AU-PANVAC).

Hester is now geared up for commercial production and marketing of its thermo-tolerant PPR vaccine from December 2020. The vaccine will be available in packs of 25, 50 and 100 doses.

Hester Biosciences Nepal is a joint venture company between Hester Biosciences and HIM Electronics set up to compliment the other range of vaccines already being produced by Hester Biosciences in India. Hester Biosciences is engaged in the manufacturing of poultry vaccines.

Hester Biosciences Share Price

2389.05 42.60 (1.82%)
01-Nov-2024 18:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1858.70
Dr. Reddys Lab 1258.55
Cipla 1559.20
Lupin 2198.25
Zydus Lifesciences 1004.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.